3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow CJM112: new trials by email Literature Review of CJM112 trials Research Report on CJM112
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma PDR001, CJM112, LCL161 - Multiple Myeloma | Phase 1 | Completed | Novartis Pharmaceuticals | 26 | 2017-12-18 | 2022-02-09 |
| A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) PDR001, ACZ885, CJM112 - Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 283 | 2016-08-23 | 2022-03-29 |
| Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis CJM112, Secukinumab, Placebo - Chronic Plaque-type Psoriasis | Phase 1 | Completed | Novartis Pharmaceuticals | 95 | 2013-06-01 | 2020-12-11 |
Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma, Ductal (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hematologic Diseases (1) · Intestinal Neoplasms (1) · Lung Neoplasms (1) · Multiple Myeloma (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Psoriasis (1) · Rectal Neoplasms (1)
United States (3) · Italy (2) · Spain (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Singapore (1) · Taiwan (1)
2016 (1)